Natural product-inspired synthesis of thiazolidine and thiazolidinone compounds and their anticancer activities

Current Pharmaceutical Design

Volumn 16, Issue 16, 2010, Pages 1826-1842

  Zhang, Qiu ^a   Zhou, Hongyu ^b   Zhai, Shumei ^a   Yan, Bing ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Anticancer; Combinatorial library approach; Natural products; Thiazolidine; Thiazolidinone

Indexed keywords

2 [5 [[5 (4 CHLOROPHENYL)FURAN 2 YL]METHYLENE] 4 OXO 2 THIOXOTHIAZOLIDIN 3 YL]ACETIC ACID DERIVATIVE; 2 ARYLTHIAZOLIDINE 4 CARBOXYLIC ACID AMIDE DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 THIAZOLIDINONE DERIVATIVE; 5 (2,4 DIHYDROXYBENZYLIDENE) 2 (PHENYLIMINO)THIAZOLIDIN 4 ONE; 5 (4 METHYLBENZYLIDENE) 2 (PHENYLIMINO)THIAZOLIDIN 4 ONE; ACETIC ACID DERIVATIVE; BENZYLIDENE DERIVATIVE; BETA LEVO DIOXALANE CYTIDINE; CIGLITAZONE; GLYCOPROTEIN P; HECTOCHLORIN; LATRUNCULIN A; MICACOCIDIN; NATURAL PRODUCT; OXAZAPHOSPHORINE DERIVATIVE; PIOGLITAZONE; RHODANINE; ROSIGLITAZONE; SORAFENIB; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CLINICAL TRIAL; COMBINATORIAL LIBRARY; CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIPOSARCOMA; MELANOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSLATION INITIATION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HUMANS; THIAZOLIDINEDIONES; THIAZOLIDINES;

EID: 77953530409     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791208983     Document Type: Article

References (160)

1. Tan LT. Bioactive natural products from marine cyanobacteria for drug discovery. Phytochemistry 2007; 68: 954-79.
2. Kashman Y, Groweiss A, Shmueli J. Latrunculin, a new 2- thiazolidinone macrolide from the marine sponge latrunculia-magnifica. Tetrahedron Lett 1980; 21: 3629-32.
3. Spector I, Shochet NR, Blasberger D, Kashman Y. Latrunculins novel marine macrolides that disrupt microfilament organization and affect cell-growth 1. comparison with cytochalasin-D. Cell Motil Cytoskel 1989; 13: 127-44.
4. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005; 96: 379-86.
5. El Sayed KA, Youssef DTA, Marchetti D. Bioactive natural and semisynthetic latrunculins. J Nat Prod 2006; 69: 219-23.
6. Longley RE, McConnell OJ, Essich E, Harmody D. Evaluation of marine sponge metabolites for cytotoxicity and signal transduction activity. J Nat Prod 1993; 56: 915-20.
7. Konishi H, Kikuchi S, Ochiai T, Ikoma H, Kubota T, Ichikawa D, et al. Latrunculin a has a strong anticancer effect in a peritoneal dissemination model of human gastric cancer in mice. Anticancer Res 2009; 29: 2091-7.
8. Kobayashi S, Hidaka S, Kawamura H, Ozaki M, Hayase Y. Micacocidin A, B and C, novel antimycoplasma agents from Pseudomonassp. - I. Taxonomy, fermentation, isolation, physicochemical properties and biological activities. J Antibiot 1998; 51: 323-7.
9. Ino A, Murabayashi A. Synthetic studies of thiazoline and thiazolidine-containing natural products - 1. Phosphorus pentachloridemediated thiazoline construction reaction. Tetrahedron 1999; 55: 10271-82.
10. Marquez BL, Watts KS, Yokochi A, Roberts MA, Verdier-Pinard P, Jimenez JI, et al. Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly. J Nat Prod 2002; 65: 866-71.
11. Suntornchashwej S, Chaichit N, Isobe M, Suwanborirux K. Hectochlorin and morpholine derivatives from the Thai sea hare, Bursatella leachii. J Nat Prod 2005; 68: 951-5.
12. Han BN, McPhail KL, Gross H, Goeger DE, Mooberry SL, Gerwick WH. Isolation and structure of five lyngbyabellin derivatives from a Papua New Guinea collection of the marine cyanobacterium Lyngbya majuscula. Tetrahedron 2005; 61: 11723-9.
13. Tomasic T, Masic LP. Rhodanine as a privileged scaffold in drug discovery. Curr Med Chem 2009; 16: 1596-629.
14. Singh SP, Parmar SS, Raman K, Stenberg VI. Chemistry and biological activity of thiazolidinones. Chem Rev 1981; 81: 175-203.
15. Verma A, Saraf SK. 4-thiazolidinone - A biologically active scaffold. Eur J Med Chem 2008; 43: 897-905.
16. Chen J, Wang Z, Lu Y, Dalton JT, Miller DD, Li W. Synthesis and antiproliferative activity of imidazole and imidazoline analogs for melanoma. Bioorg Med Chem Lett 2008; 18: 3183-7.
17. Gududuru V, Hurh E, Dalton JT, Miller DD. Discovery of 2- arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer. J Med Chem 2005; 48: 2584-8.
18. Sriharsha SN, Satish S, Shashikanth S, Raveesha KA. Design, synthesis and antibacterial activity of novel 1,3-thiazolidine pyrimidine nucleoside analogues. Biorg Med Chem 2006; 14: 7476-81.
19. Lesyk RB, Zimenkovsky BS. 4-thiazolidones: Centenarian history, current status and perspectives for modern organic and medicinal chemistry. Curr Org Chem 2004; 8: 1547-77.
20. Shiradkar MR, Ghodake M, Bothara KG, Bhandari SV, Nikalje A, Akula KC, et al. Synthesis and anticonvulsant activity of clubbed thiazolidinone-barbituric acid and thiazolidinone-triazole derivatives. Arkivoc 2007; 58-74.
21. Zhou HY, Wu SH, Zhai SM, Liu AF, Sun Y, Li RS, et al. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem 2008; 51: 1242-51.
22. Janovec L, Sabolova D, Kozurkova M, Paulikova H, Kristian P, Ungvarsky J, et al. Synthesis, DNA interaction, and cytotoxic activity of a novel proflavine-dithiazolidinone pharmacophore. Bioconjugate Chem 2007; 18: 93-100.
23. Kline T, Felise HB, Barry KC, Jackson SR, Nguyen HV, Miller SI. Substituted 2-Imino-5-arylidenethiazolidin-4-one Inhibitors of Bacterial Type III Secretion. J Med Chem 2008; 51: 7065-74.
24. Kasmi-Mir S, Djafri A, Paquin L, Hamelin J, Rahmouni M. One- pot synthesis of 5-arylidene-2-imino-4-thiazolidinones under microwave irradiation. Molecules 2006; 11: 597-602.
25. Ottana R, Maccari R, Barreca ML, Bruno G, Rotondo A, Rossi A, et al. 5-arylidene-2-imino-4-thiazolidinones: Design and synthesis of novel anti-inflammatory agents. Biorg Med Chem 2005; 13: 4243-52.
26. Parmar SS, Chaudhar A, Gupta TK, Dwivedi C. Substituted thiazolidones and their selective-inhibition of nicotinamide-adenine dinucleotide dependent oxidations. J Med Chem 1972; 15: 99-100.
27. Bourahla K, Derdour A, Rahmouni M, Carreaux F, Bazureau JP. A practical access to novel 2-amino-5-arylidene-1,3-thiazol-4(5H)- ones via sulfur/nitrogen displacement under solvent-free micro- wave irradiation. Tetrahedron Lett 2007; 48: 5785-9.
28. Taylor EC, Wolinsky J, Lee HH. The reaction of alpha-cyano- benzyl benzenesul fonate with dithiocarbamates. J Amer Chem Soc 1954; 76: 1870-2.
29. Hu BH, Malamas M, Ellingboe J. Synthesis of heterocycle substituted 1-aryl-4-piperidones. Heterocycles 2002; 57: 857-70.
30. Hu BH, Malamas M, Ellingboe J, Largis E, Han S, Mulvey R, et al. New oxadiazolidinedione derivatives as potent and selective human beta(3) agonists. Bioorg Med Chem Lett 2001; 11: 981-4.
31. Chen SQ, Chen L, Le NT, Zhao CL, Sidduri A, Lou JP, et al. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors. Bioorg Med Chem Lett 2007; 17: 2134-8.
32. Yan SQ, Appleby T, Larson G, Wu JZ, Hamatake R, Hong Z, et al. Structure-based design of a novel thiazolone scaffold as HCVNS5B polymerase allosteric inhibitors. Bioorg Med Chem Lett 2006; 16: 5888-91.
33. Song YT, Connor DT, Doubleday R, Sorenson RJ, Sercel AD, Unangst PC, et al. Synthesis, structure - Activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. J Med Chem 1999; 42: 1151-60.
34. Janusz JM, Young PA, Ridgeway JM, Scherz MW, Enzweiler K, Wu LI, et al. New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Variations at the 5 position. J Med Chem 1998; 41: 3515-29.
35. Unangst PC, Connor DT, Cetenko WA, Sorenson RJ, Kostlan CR, Sircar JC, et al. Synthesis and biological evaluation of 5-[[3,5- bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles, - thiazoles and -imidazoles -novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J Med Chem 1994; 37: 322-8.
36. Wu S, Guo W, Teraishi F, Pang J, Kaluarachchi K, Zhang L, et al. Anticancer activity of 5-benzylidene-2-phenylimino-1, 3- thiazolidin-4-one (BPT) analogs. Med Chem 2006; 2: 597-605.
37. Pulici M, Quartieri F. Traceless solid-phase synthesis of 2-amino- 5-alkylidene-thiazol-4-ones. Tetrahedron Lett 2005; 46: 2387-91.
38. Kato T, Ozaki T, Tamura K, Suzuki Y, Akima M, Ohi N. Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 2. Structure-activity relationships of thiazolidinone derivatives. J Med Chem 1999; 42: 3134-46.
39. Allen S, Newhouse B, Anderson AS, Fauber B, Allen A, Chantry D, et al. Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists. Bioorg Med Chem Lett 2004; 14: 1619-24.
40. Fraga-Dubreuil J, Bazureau JP. Efficient combination of task- specific ionic liquid and microwave dielectric heating applied to one-pot three component synthesis of a small library of 4- thiazolidinones. Tetrahedron 2003; 59: 6121-30.
41. Gududuru V, Hurh E, Dalton JT, Miller DD. Synthesis and antiprofilerative activity of 2-arly-4-oxo-thiazolidin-3-yl-amides for prostate cancer. Bioorg Med Chem Lett 2004; 14: 5289-93.
42. Holmes CP, Chinn JP, Look GC, Gordon EM, Gallop MA. Strategies for combinatorial organic-synthesis-solution and polymer-supported synthesis of 4-thiazolidinones and 4-metathiazanones derived from amino-acids. J Org Chem 1995; 60: 7328-33.
43. Rawal RK, Prabhakar YS, Katti SB, De Clercq E. 2-(Aryl)-3-furan- 2-ylmethyl-thiazolidin-4-ones as selective HIV-RT Inhibitors. Bioorg Med Chem 2005; 13: 6771-6.
44. Rawal RK, Tripathi R, Katti SB, Pannecouque C, De Clercq E. Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3- thiazolidin-4-ones as anti-HIV agents. Bioorg Med Chem 2007; 15: 1725-31.
45. Srivastava T, Gaikwad AK, Haq W, Sinha S, Katti SB. Synthesis and biological evaluation of 4-thiazolidinone derivatives as potential antimycobacterial agents. Arkivoc 2005; 120-30.
46. Srivastava T, Haq W, Katti SB. Carbodiimide mediated synthesis of 4-thiazolidinones by one-pot three-component condensation. Tetrahedron 2002; 58: 7619-24.
47. Zhou HY, Liu AF, Li XF, Ma XF, Feng W, Zhang W, et al. Microwave-assisted fluorous synthesis of 2-aryl-substituted 4- thiazolidinone and 4-thiazinanone libraries. J Comb Chem 2008; 10: 303-12.
48. Geronikaki A, Eleftheriou P, Vicini P, Alam I, Dixit A, Saxena AK. 2-thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action. J Med Chem 2008; 51: 5221-8.
49. Le Marechal AM, Robert A, Leban I. Gem-dicyano epoxide synthetic equivalents of dicationic ketenes: synthesis of 4- thiazolidinones by reaction with substituted thioureas and preparation of 2-[aryl(cyanocarbonyl)methylene]benzoxazoles by reaction with 2-thioxobenzoxazoles Tetrahedron 1990; 46: 453-64.
50. Volmajer J, Toplak R, Bittner S, Le Marechal AM. 2-oxirane- carbonitriles in the synthesis of linked quinono heterocyclic derivatives. Arkivoc 2003; 49-61.
51. Rajanarendar E, Karunakar D, Ramu K. Synthesis of 5-methyl-2- [2-methyl/phenylimino-3-(3-methyl-5-styryl-isoxazol-4-yl)-2,3 - dihydro-thiazole-4-carbonyl]-2,4-dihydro-pyrazol-3-ones, 1,3,4- oxadiazoles and 4-oxo-thiazolin-5-ylidene-acetic acid methyl esters. Heterocycl Commun 2006; 12: 123-8.
52. Sarodnick G, Heydenreich M, Linker T, Kleinpeter E. Quinoxalines. Part 12: synthesis and structural study of 1-(thiazol- 2-yl)-1H-pyrazolo[3,4-b]quinoxalines - the dehydrogenative cyclization with hydroxylamine hydrochloride. Tetrahedron 2003; 59: 6311-21.
53. Metwally NH. Efficient Synthesis of Highly Substituted Furan, Thiophene, Pyrrole and 2-Aminothiazole Derivatives. Synth Commun 2007; 37: 4227-37.
54. Blanchet J, Zhu JP. Reeve's synthesis of 2-imino-4-thiazolidinone from alkyl (aryl) trichloromethylcarbinol revisited, a three- component process from aldehyde, chloroform and thiourea. Tetrahedron Lett 2004; 45: 4449-52.
55. Cossy J, Menciu C, Rakotoarisoa H, Kahn PH, Desmurs JR. A short synthesis of troglitazone: An antidiabetic drug for treating insulin resistance. Bioorg Med Chem Lett 1999; 9: 3439-40.
56. Fan YH, Chen H, Natarajan A, Guo Y, Harbinski F, Iyasere J, et al. Structure-activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorg Med Chem Lett 2004; 14: 2547-50.
57. Huang JW, Shiau CW, Yang J, Wang DS, Chiu HC, Chen CY, et al. Development of small-molecule cyclin D1-ablative agents. J Med Chem 2006; 49: 4684-9.
58. Sonawane ND, Verkman AS. Thiazolidinone CFTR inhibitors with improved water solubility identified by structure-activity analysis. Biorg Med Chem 2008; 16: 8187-95.
59. Gabillet S, Lecercle D, Loreau O, Carboni M, Dezard S, Gomis JM, et al. Phosphine-catalyzed construction of sulfur heterocycles. Org Lett 2007; 9: 3925-7.
60. Alizadeh A, Rostamnia S, Zohreh N, Hosseinpour R. A simple and effective approach to the synthesis of rhodanine derivatives via three-component reactions in water. Tetrahedron Lett 2009; 50: 1533-5.
61. El-Aasar NK, Saied KF. Synthesis of new thiazolidine and imidazolidine derivatives of pharmacological interest. J Heterocycl Chem 2008; 45: 645-652.
62. Zimenkovskii BS, Kutsyk RV, Lesyk RB, Matyichuk VC, Obushak ND, Klyufinskaya TI. Synthesis and antimicrobial activity of 2,4- dioxothiazolidine-5-acetic acid amides. Khimiko-Farmatsevticheskii Zhurnal 2006; 40: 13-16.
63. Zask A, Jirkovsky I, Nowicki JW, McCaleb ML. Synthesis and antihyperglycemic activity of novel 5-(naphthalenylsulfonyl)-2,4- thiazolidinediones. J Med Chem 1990; 33: 1418-1423.
64. Casillas T, Delicado EG, Garcia-Carmona F, Miras-Portugal MT. Kinetic and allosteric cooperativity in L-adenosine transport in chromaffin cells. A mnemonical transporter. Biochemistry 1993; 32: 14203-14209.
65. Sriharsha SN, Pai KSR, Suhas, Shashikanth S, Chandra N, Prabhu KR. Synthesis, docking and anti-tumor activity of beta-L-1,3- thiazolidine pyrimidine nucleoside analogues. Med Chem 2007; 3: 425-32.
66. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
67. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995; 64: 721-62.
68. Gududuru V, Hurh E, Durgam GG, Hong SS, Sardar VM, Xu HP, et al. Synthesis and biological evaluation of novel cytotoxic phospholipids for prostate cancer. Bioorg Med Chem Lett 2004; 14: 4919-23.
69. Li W, Lu Y, Wang Z, Dalton JT, Miller DD. Synthesis and antiproliferative activity of thiazolidine analogs for melanoma. Bioorg Med Chem Lett 2007; 17: 4113-7.
70. Voelcker G, Bielicki L, Hohorst HJ. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation. J Cancer Res Clin Oncol 1997; 123: 623-31.
71. Voelcker G, Hohorst HJ. Structure/activity studies with thiazolidinyl- and perhydrothiazinyl-phosphamide ester. J Cancer Res Clin Oncol 1998; 124: 297-300.
72. Liang J, Huang M, Duan W, Yu XQ, Zhou SF. Design of new oxazaphosphorine anticancer drugs. Current Pharm Design 2007; 13: 963-78.
73. Wu S, Guo W, Teraishi F, Pang J, Kaluarachchi K, Zhang L, et al. Anticancer activity of 5-benzylidene-2-phenylimino-1, 3- thiazolidin-4-one (BPT) analogs. Med Chem 2006; 2: 597-605.
74. Teraishi F, Wu SH, Sasaki J, Zhang LD, Zhu HB, Davis JJ, et al. P-glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2- (phenylamino)-4 (5H)-thiazolone]. J Pharmacol Exp Ther 2005; 314: 355-62.
75. Teraishi F, Wu SH, Zhang LD, Guo W, Davis JJ, Dong FQ, et al. Identification of a novel synthetic thiazolidin compound capable of inducing c-Jun NH2-tkinase-dependent apoptosis in human colon cancer cells. Cancer Res 2005; 65: 6380-7.
76. Teraishi F, Wu S, Sasaki J, Zhang L, Davis JJ, Guo W, et al. JNK1-dependent antimitotic activity of thiazolidin compounds in human non-small-cell lung and colon cancer cells. Cell Mol Life Sci 2005; 62: 2382-9.
77. Kumar CC, Armstrong L, Yin Z, Malkowski M, Maxwell E, Ling H, et al. Targeting integrins alpha(v)beta(3) and alpha(v)beta(5) for blocking tumor-induced angiogenesis. Angiogenesis 2000; 476: 169-80.
78. Shannon KE, Keene JL, Settle SL, Duffin TD, Nickols MA, Westlin M, et al. Anti-metastatic properties of RGD-pepti- domimetic agents S137 and S247. Clin Exp Metast 2004; 21: 129-38.
79. Fischer PM, Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependant kinase inhibitors. Expert Opin Invest Drugs 2005; 14: 457-77.
80. Dayam R, Aiello F, Deng JX, Wu Y, Garofalo A, Chen XY, et al. Discovery of small molecule integrin alpha(v)beta(3) antagonists as novel anticancer agents. J Med Chem 2006; 49: 4526-34.
81. Havrylyuk D, Zimenkovsky B, Vasylenko O, Zaprutko L, Gzella A, Lesyk R. Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur J Med Chem 2009; 44: 1396-1404.
82. Chen H, Fan YH, Natarajan A, Guo YH, Iyasere J, Harbinski F, et al. Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorg Med Chem Lett 2004; 14: 5401-5.
83. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-x(L). Nat Cell Biol 2001; 3: 173-82.
84. Lugovskoy AA, Degterev AI, Fahmy AF, Zhou P, Gross JD, Yuan JY, et al. A novel approach for characterizing protein ligand complexes: molecular basis for specificity of small-molecule Bcl-2 inhibitors. J Am Chem Soc 2002; 124: 1234-40.
85. Ahn JH, Kim SJ, Park WS, Cho SY, Ha JD, Kim SS, et al. Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg Med Chem Lett 2006; 16: 2996-9.
86. Park H, Jung SK, Jeong DG, Ryu SE, Kim SJ. Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening. Bioorg Med Chem Lett 2008; 18: 2250-5.
87. Cutshall NS, O'Day C, Prezhdo M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg Med Chem Lett 2005; 15: 3374-9.
88. Huwiler A, Zangemeister-Wittke U. Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit Rev Oncol Hematol 2007; 63: 150-9.
89. Chandrappa S, Kavitha CV, Shahabuddin MS, Vinaya K, Kumar CSA, Ranganatha SR, et al. Synthesis of 2-(5-((5-(4-chloro- phenyl)furan-2-yl)methylene)-4-oxo-2-thioxo-thiazolidin-3-yl) acetic acid derivatives and evaluation of their cytotoxicity and induction of apoptosis in human leukemia cells. Biorg Med Chem 2009; 17: 2576-84.
90. Hafez HN, El-Gazzar A. Synthesis and antitumor activity of substituted triazolo[4,3-a]pyrimidin-6-sulfonamide with an incorporated thiazolidinone moiety. Bioorg Med Chem Lett 2009; 19: 4143-7.
91. Abd Elhafez OM, El Khrisy E, Badria F, Fathy AED. Synthesis and biological investigations of new thiazolidinone and oxadiazoline coumarin derivatives. Arch Pharmacal Res 2003; 26: 686-96.
92. Kawakami M, Koya K, Ukai T, Tatsuta N, Ikegawa A, Ogawa K, et al. Synthesis and evaluation of novel rhodacyanine dyes that exhibit antitumor activity. J Med Chem 1997; 40: 3151-60.
93. Kawakami M, Koya K, Ukai T, Tatsuta N, Ikegawa A, Ogawa K, et al. Structure-activity of novel rhodacyanine dyes as antitumor agents. J Med Chem 1998; 41: 130-42.
94. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med 1999; 16: 179-92.
95. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPAR gamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006; 6.
96. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95: 8806-11.
97. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1: 330-9.
98. Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, et al. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005; 67: 1342-8.
99. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator- activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther 2009; 8: 6-15.
100. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-70.
101. Yin F, Wakino S, Liu ZW, Kim S, Hsueh WA, Collins AR, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 2001; 286: 916-22.
102. Brockman JA, Gupta RA, DuBois RN. Activation of PPAR gamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 1998; 115: 1049-55.
103. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000; 60: 1129-38.
104. Fujimura S, Suzumiya J, Nakamura K, Ono J. Effects of troglitazone on the growth and differentiation of hematopoietic cell lines. Int J Oncol 1998; 13: 1263-7.
105. Kato M, Kusumi T, Tsuchida S, Tanaka M, Sasaki M, Kudo H. Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 2004; 130: 73-9.
106. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 3344-52.
107. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells. Cancer Res 2000; 60: 5558-64.
108. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86: 2170-7.
109. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med 1998; 4: 1046-52.
110. Takahashi N, Okumura T, Motomura L, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455: 135-9.
111. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270: 400-5.
112. Bae MA, Rhee H, Song BJ. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apopiosis in human and rat hepatoma cell lines. Toxicol Lett 2003; 139: 67-75.
113. Bae MA, Song BJ. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol Pharmacol 2003; 63: 401-8.
114. Kim KY, Ahn JH, Cheon HG. Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non- small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation. Mol Pharmacol 2007; 72: 674-85.
115. Koga H, Harada M, Ohtsubo M, Shishido S, Kumemura H, Hanada S, et al. Troglitazone induces p27(Kip1)-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 2003; 37: 1086-96.
116. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 2000; 97: 10990-5.
117. Schultze K, Bock B, Eckert A, Oevermann L, Ramacher D, Wiestler O, et al. Troglitazone sensitizes tumor cells to TRAIL- induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 2006; 11: 1503-12.
118. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, et al. 15S-hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001; 61: 497-503.
119. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR-gamma. Cancer Res 2005; 65: 1561-9.
120. Yang CC, Wang YC, Wei S, Lin LF, Chen CS, Lee CC, et al. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation. Cancer Res 2007; 67: 3229-38.
121. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Minuto M, et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol 2009; 70: 946-53.
122. Butler R, Mitchell SH, Tindall DJ, Young CYF. Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15- deoxy-Delta(12,14)-prostaglandin J(2). Cell Growth Differentiation 2000; 11: 49-61.
123. Cao LQ, Wang XL, Wang Q, Xue P, Jiao XY, Peng HP, et al. Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5- fluorouracil antitumor activity through activation of the PPAR gamma signaling pathway. Acta Pharm Sci 2009; 30: 1316-22.
124. Hazra S, Dubinett SM. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells. Prostag Leukotr Ess 2007; 77: 51-8.
125. Li MY, Lee TW, Yim APC, Mok TSK, Chen GG. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells. J Cell Physiol 2006; 209: 428-38.
126. Takano S, Kubota T, Nishibori H, Hasegawa H, Ishii Y, Nitori N, et al. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. Anticancer Res 2008; 28: 3593-9.
127. Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CDM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997; 94: 237-41.
128. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncology 2004; 5: 419-29.
129. Jiang M, Shappell SB, Hayward SW. Approaches to understanding the importance and clinical implications of peroxisome proliferator-activated receptor gamma (PPAR gamma) signaling in prostate cancer. J Cell Biochem 2004; 91: 513-27.
130. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 2003; 9: 1-9.
131. Kopelovich L, Fay JR, Glazer RI, Crowell JA. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 2002; 1: 357-63.
132. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 2006; 13: 401-13.
133. Demetri GD, Fletcher CDM, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglita- zone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96: 3951-6.
134. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001; 61: 2424-8.
135. Yu J, Qiao L, Zimmermann L, Ebert MPA, Zhang HX, Lin W, et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 2006; 43: 134-43.
136. Hisatake J, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res 2000; 60: 5494-8.
137. Jozkowicz A, Dulak J, Piatkowska E, Placha W, Dembinska-Kiec A. Ligands of peroxisome proliferator-activated receptor-gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim Pol 2000; 47: 1147-57.
138. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409-12.
139. Murtola TJ, Pennanen P, Syvala H, Blauer M, Ylikomi T, Tammela TLJ. Effects of simvastatin, acetylsalicylic acid, and rosigli-tazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate 2009; 69: 1017-1023.
140. Lyles BE, Akinyeke TO, Moss PE, Stewart LV. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPAR gamma-dependent and PPAR gamma-independent pathways. Cell Cycle 2009; 8: 268-77.
141. Lin MS, Chen WC, Bai X, Wang YD. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. J Dig Dis 2007; 8: 82-8.
142. Mehta RG, Williamson E, Patel MK, Koeffler HP. A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 2000; 92: 418-23.
143. Wei S, Yang J, Lee SL, Kulp SK, Chen CS. PPAR gamma- independent antitumor effects of thiazolidinediones. Cancer Lett 2009; 276: 119-24.
144. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001; 61: 6213-8.
145. Okura T, Nakamura M, Takata Y, Watanabe S, Kitami Y, Hiwada K. Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. Eur J Pharmacol 2000; 407: 227-35.
146. Kim Y, Suh N, Sporn M, Reed JC. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL- induced apoptosis. J Biol Chem 2002; 277: 22320-9.
147. Liu JJ, Farmer SR. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis - A glycogen synthase kinase 3 beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 2004; 279: 45020-7.
148. Moldes M, Zuo Y, Morrison RF, Silva D, Park BH, Liu JJ, et al. Peroxisome-proliferator-activated receptor gamma suppresses Wnt/beta-catenin signalling during adipogenesis. Biochem J 2003; 376: 607-13.
149. Sharma C, Pradeep A, Wong L, Rana A, Rana B. Peroxisome proliferator-activated receptor gamma activation can regulate betacatenin levels via a proteasome-mediated and adenomatous poly- posis coli-independent pathway. J Biol Chem 2004; 279: 35583-94.
150. Wei S, Lin LF, Yang CC, Wang YC, Chang GD, Chen H, et al. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-Box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma. Mol Pharmacol 2007; 72: 725-33.
151. Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, et al. Activation of peroxisome proliferator- activated receptor gamma by a novel synthetic triterpenoid 2- cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 2003; 63: 5926-39.
152. Qin CH, Burghardt R, Smith R, Wormke M, Stewart J, Safe S. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 2003; 63: 958-64.
153. Wang CG, Fu MF, D'Amico M, Albanese C, Zhou JN, Brownlee M, et al. Inhibition of cellular proliferation through I kappa B kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Bio 2001; 21: 3057-70.
154. Yang CC, Ku CY, Wei S, Shiau CW, Chen CS, Pinzone JJ, et al. Peroxisome proliferator-activated receptor gamma-independent repression of prostate-specific antigen expression by thiazolidinediones in prostate cancer cells. Mol Pharmacol 2006; 69: 1564-70.
155. Yang J, Wei S, Wang DS, Wang YC, Kulp SK, Chen CS. Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents. J Med Chem 2008; 51: 2100-7.
156. Cho H, Tai HH. Thiazolidinediones as a novel class of NAD(+)- dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Arch Biochem Biophys 2002; 405: 247-51.
157. Beharry Z, Zemskova M, Mahajan S, Zhang FX, Ma J, Xia ZP, et al. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther 2009; 8: 1473-83.
158. Xia ZP, Knaak C, Ma J, Beharry ZM, McInnes C, Wang WX, et al. Synthesis and Evaluation of Novel Inhibitors of Pim-1 and Pim-2 Protein Kinases. J Med Chem 2009; 52: 74-86.
159. Chandrappa S, Prasad SBB, Vinaya K, Kumar CSA, Thimme-gowda NR, Rangappa KS. Synthesis and in vitro antiproliferative activity against human cancer cell lines of novel 5-(4-methyl- benzylidene)-thiazolidine-2,4-diones. Invest New Drug 2008; 26: 437-44.
160. Dawson MI, Xia ZB, Liu G, Fontana JA, Farhana L, Patel BB, et al. An adamantyl-substituted retinoid-derived molecule that inhibits cancer cell growth and angiogenesis by inducing apoptosis and binds to small heterodimer partner nuclear receptor: Effects of modifying its carboxylate group on apoptosis, proliferation, and protein-tyrosine phosphatase activity. J Med Chem 2007; 50: 2622-39.